Ascendo Biotechnology Co., Ltd.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
Our pipeline is driven by our revolutionary research into immune response. Each product builds on our unique understanding of innate immunity and how this natural control can be used to destroy solid tumors or calm autoimmune inflammation. ASD141, our fir
The content above was translated by Ai
Founded Year
2023
Unified Business No.
83000625
Status
Active
Number of Employees
0
Total Paid-in
Capital
242,420,000 (NT$)
Location of Company
Taiwan
, Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Ascendo Biotechnology is a clinical-stage pharmaceutical company founded in 2019. We leverage cutting-edge research in the field of dysregulated immune function to develop novel immunotherapy solutions for cancer and autoimmune diseases.
The content above was translated by Ai
